We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Immunological Tests Are Superior for Colon Cancer Screening

By LabMedica International staff writers
Posted on 18 Jul 2013
Print article
Image: OC-Sensor fully automated fecal occult blood analyzer (Photo courtesy of Eiken Chemical).
Image: OC-Sensor fully automated fecal occult blood analyzer (Photo courtesy of Eiken Chemical).
The fecal immunochemical tests (FITs) for hemoglobin offer a number of advantages over traditional guaiac based fecal occult blood tests (gFOBTs).

The major advantage seems to come at the price of higher positivity rates and lower specificity and hence a higher load of work-up colonoscopies, which makes a final judgment of the superiority of either test difficult.

Scientists from the German Cancer Research Center (Heidelberg, Germany) compared three quantitative FITs with a gFOBT among participants of the German screening colonoscopy program. They obtained stool samples and colonoscopy reports from 2,235 participants of screening colonoscopy from 2005 to 2009. Patients willing to participate were given stool collection instructions and devices, including a small container and one test card for a gFOBT (HemOccult, Beckman Coulter; Krefeld, Germany).

The stored stool samples were assayed with two automated, enzyme-linked immunosorbent assay (ELISA) based FITs, RIDASCREEN Haemoglobin, and RIDASCREEN Haemo-/Haptoglobin Complex, (R-Biopharm AG; Darmstadt, Germany). Cut-offs for positivity was 2 μg hemoglobin per gram stool. The stool samples were further analyzed, including a third FIT, OC-SENSOR, (Eiken Chemical; Tokyo, Japan).

The enzyme-based test detected one third of all colon cancer cases, about 9% of advanced precancerous adenomas lesions, and about 5% of early precancerous lesions. In 95 out of 100 participants with negative test results, no tissue abnormalities were found in the subsequent colonoscopy. Despite the already high specificities of the gFOBT for all outcomes, ranging from 95.2% to 95.4%, specificities were even higher for each of the FITs and each outcome. With estimates between 96.8% and 97.8%, specificities with respect to the detection of any cancer or any advanced neoplasm were very high for all three FITs.

Hermann Brenner, MD, MPH, a professor of clinical epidemiology, and senior author of the study said, “For the first time we have shown by direct comparison that the diagnostic performance of immunological stool tests is significantly higher than that of the enzymatic test at the same rate of positive results. Tests for occult blood in the stool will continue to be an important part of colon cancer screening. We therefore recommend including immunological tests in cancer screening programs in Germany. Many more people would thus benefit by obtaining a life-saving clue pointing to a hidden case of cancer.” The study was published on May 22, 2013, in the European Journal of Cancer.

Related Links:

Beckman Coulter
R-Biopharm
Eiken Chemical



HLX
New
Gold Supplier
hCG Whole Blood Pregnancy Test
VEDALAB hCG-CHECK-1
New
Cardiac Test
ImmunTech Cardiac Triple Test
New
PCR Fluorescent Quantitative System
AccuRa mini

Print article

Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The Coris acquisition provides Avacta with a broad, professional-use rapid test product portfolio (Photo courtesy of Coris Bioconcept)

Avacta Expands Diagnostics Portfolio with Acquisition of Rapid Test Maker Coris Bioconcept

Avacta Group plc (London, UK), a life sciences company developing oncology drugs and diagnostics, has acquired Coris Bioconcept SRL (Gembloux, Belgium) for an upfront cash consideration of GBP 7.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.